From: Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
S. No. | Drug | Molecular targets | Phases of clinical trial | Year and references |
---|---|---|---|---|
1 | Tremelimumab | CTLA-4 | II | 2013 [141] |
2 | Icaritin | IL-6/Jak2/Stat3 | II | 2015 [142] |
3 | Lenalidomide | TNF-α, interferon γ, IL-6, IL-10, and IL-12. | II | 2015 [143] |
4 | Codrituzumab | Glypican-3 | II | 2016 [144] |
5 | Nivolumab | PD-1 | I | 2016 [145] |
6 | Ipilimumab | CTLA-4 | II | 2017 [146] |
7 | Tasquinimod | Protein S100A9 | II | 2017 [147] |